Aspects of the cellular pharmacology of N-l-leucyldoxorubicin in human tumor cell lines.

[1]  J. Robert,et al.  Human pharmacokinetics of N‐l‐leucyl‐doxorubicin, a new anthracycline derivative, and its correlation with clinical toxicities , 1992, Clinical pharmacology and therapeutics.

[2]  A. Viel,et al.  Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines , 1991, British Journal of Cancer.

[3]  V. Ling,et al.  Mechanism of multidrug resistance. , 1988, Biochimica et biophysica acta.

[4]  S. Doglia,et al.  Quantitative study of doxorubicin in living cell nuclei by microspectrofluorometry. , 1988, Biochimica et biophysica acta.

[5]  N. Mulder,et al.  Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. , 1987, Cancer research.

[6]  James B. Mitchell,et al.  Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. , 1987, Cancer research.

[7]  A. Tulpule,et al.  Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. , 1986, The Journal of biological chemistry.

[8]  R. Jaenke,et al.  Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit. , 1980, Cancer research.

[9]  A. Trouet,et al.  Rapid determination of doxorubicin and its fluorescent metabolites by high pressure liquid chromatography. , 1979, Analytical biochemistry.

[10]  P. Wilkinson,et al.  Liquid Chromatographic Analysis of Adriamycin and Metabolites in Biological Fluids , 1978 .

[11]  C. Lozzio,et al.  Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. , 1975, Blood.

[12]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.